FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W229384513> ?p ?o ?g. }

• W229384513 endingPage "42" @default.
• W229384513 startingPage "38" @default.
• W229384513 abstract "No AccessJournal of Urology1 Jul 1980Bacillus Calmette-guerin Immunotherapy of Superficial Bladder Cancer Donald L. Lamm, Daniel E. Thor, Steven C. Harris, Juan A. Reyna, Valerie D. Stogdill, and Howard M. Radwin Donald L. LammDonald L. Lamm More articles by this author , Daniel E. ThorDaniel E. Thor More articles by this author , Steven C. HarrisSteven C. Harris More articles by this author , Juan A. ReynaJuan A. Reyna More articles by this author , Valerie D. StogdillValerie D. Stogdill More articles by this author , and Howard M. RadwinHoward M. Radwin More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)55282-9AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Thirty-seven patients were enrolled in a randomized prospective study to compare standard surgical therapy for superficial bladder cancer to standard therapy plus bacillus Calmette-Guerin (BCG). Side effects of BCG have been tolerated well and include dysuria in 95 per cent of the patients, urinary frequency in 83 per cent, hematuria in 39 per cent, fever in 22 per cent and nausea in 22 per cent. Of 19 control patients 8 (42 per cent) had recurrent tumors in the followup period, compared to 3 of 18 patients (17 per cent) treated with BCG. One patient treated with BCG had 2 recurrences, yielding a recurrence rate of 22 per cent in the group receiving BCG compared to 42 per cent in controls. When the incidence of recurrent tumors in matched intervals before and after entry into the protocol is compared, no change in the rate of tumor recurrence (p equals 0.726 chi-square) occurred in controls, whereas tumor recurrences were reduced significantly in the group treated with BCG (p equals 0.010 chi-square). The reduction in tumor recurrence in patients treated with BCG compared to controls is statistically significant (p equals 0.029 chi-square). Of 4 patients with previous stage B disease treated with BCG 3 have remained free of tumor. Three patients who presented with new bladder tumors remain free of tumor after BCG therapy, while 2 of 5 comparable control patients developed recurrent tumors. Intravesical and percutaneous BCG immunotherapy appears to decrease the rate of tumor recurrence in patients followed for 1 year. © 1980 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byMcElree I, Steinberg R, Martin A, Richards J, Mott S, Gellhaus P, Nepple K, O'Donnell M and Packiam V (2022) Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder CancerJournal of Urology, VOL. 208, NO. 3, (589-599), Online publication date: 1-Sep-2022.Donin N, Lenis A, Holden S, Drakaki A, Pantuck A, Belldegrun A and Chamie K (2018) Immunotherapy for the Treatment of Urothelial CarcinomaJournal of Urology, VOL. 197, NO. 1, (14-22), Online publication date: 1-Jan-2017.Sfakianos J, Kim P, Hakimi A and Herr H (2018) The Effect of Restaging Transurethral Resection on Recurrence and Progression Rates in Patients with Nonmuscle Invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-GuérinJournal of Urology, VOL. 191, NO. 2, (341-345), Online publication date: 1-Feb-2014.Herr H and Morales A (2018) History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Success StoryJournal of Urology, VOL. 179, NO. 1, (53-56), Online publication date: 1-Jan-2008.Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L and Rischmann P (2018) The Effect of Ofloxacin on Bacillus Calmette-Guerin Induced Toxicity in Patients With Superficial Bladder Cancer: Results of a Randomized, Prospective, Double-Blind, Placebo Controlled, Multicenter StudyJournal of Urology, VOL. 176, NO. 3, (935-939), Online publication date: 1-Sep-2006.PALOU J, LAGUNA P, MILLÁN-RODRÍGUEZ F, HALL R, SALVADOR-BAYARRI J and VICENTE-RODRÍGUEZ J (2018) CONTROL GROUP AND MAINTENANCE TREATMENT WITH BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU AND/OR HIGH GRADE BLADDER TUMORSJournal of Urology, VOL. 165, NO. 5, (1488-1491), Online publication date: 1-May-2001.LAMM D, BLUMENSTEIN B, CRISSMAN J, MONTIE J, GOTTESMAN J, LOWE B, SAROSDY M, BOHL R, GROSSMAN H, BECK T, LEIMERT J and CRAWFORD E (2018) MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDYJournal of Urology, VOL. 163, NO. 4, (1124-1129), Online publication date: 1-Apr-2000.ALI-EL-DEIN B, NABEEH A, ISMAIL E and GHONEIM M (2018) SEQUENTIAL BACILLUS CALMETTE-GUERIN AND EPIRUBICIN VERSUS BACILLUS CALMETTE-GUERIN ALONE FOR SUPERFICIAL BLADDER TUMORS: A RANDOMIZED PROSPECTIVE STUDYJournal of Urology, VOL. 162, NO. 2, (339-342), Online publication date: 1-Aug-1999.Wishahi M, Ismail I, Ruebben H and Otto T (2018) Original Articles: Bladder Cancer: Keyhole-Limpet Hemocyanin Immunotherapy in the Bilharzial Bladder: A New Treatment Modality? Phase II Trial: Superficial Bladder CancerJournal of Urology, VOL. 153, NO. 3S, (926-928), Online publication date: 1-Mar-1995.Lamm D, Riggs D, Shriver J, vanGilder P, Rach J and DeHaven J (2018) Megadose Vitamins in Bladder Cancer: A Double-Blind Clinical TrialJournal of Urology, VOL. 151, NO. 1, (21-26), Online publication date: 1-Jan-1994.Hakim S, Heaney J, Heinz T and Zwolak R (2018) Psoas Abscess Following Intravesical Bacillus Calmette-Guerin for Bladder Cancer: A Case ReportJournal of Urology, VOL. 150, NO. 1, (188-189), Online publication date: 1-Jul-1993.Cookson M and Sarosdy M (2018) Management of Stage T1 Superficial Bladder Cancer with Intravesical Bacillus Calmette-Guerin TherapyJournal of Urology, VOL. 148, NO. 3 Part 1, (797-801), Online publication date: 1-Sep-1992.Molina J, Rabian C, D’agay M and Modai J (2018) Hypersen sitivity Systemic Reaction Following Intravesical Bacillus Calmette-Guerin: Successful Treatment With SteroidsJournal of Urology, VOL. 147, NO. 3 Part 1, (695-697), Online publication date: 1-Mar-1992.Levi D’Ancona C, Rodrigues Netto N, Almeida Claro J and Ikari O (2018) Oral or Intravesical Bacillus Calmette-Guerin Immunoprophylaxis in Bladder CarcinomaJournal of Urology, VOL. 145, NO. 3, (498-501), Online publication date: 1-Mar-1991.Martínez Piñeiro J, León J, Martínez Piñeiro L, Fiter L, Mosteiro J, Navarro J, García Matres M and Cárcamo P (2018) Bacillus Calmette-Guerin Versus Doxorubicin Versus Thiotepa: A Randomized Prospective Study in 202 Patients with Superficial Bladder CancerJournal of Urology, VOL. 143, NO. 3, (502-506), Online publication date: 1-Mar-1990.Sarosdy M and Lamm D (2018) Long-Term Results of Intravesical Bacillus Calmette-Guerin Therapy for Superficial Bladder CancerJournal of Urology, VOL. 142, NO. 3, (719-722), Online publication date: 1-Sep-1989.Herr H (2018) Editorial CommentJournal of Urology, VOL. 142, NO. 3, (722-722), Online publication date: 1-Sep-1989.Linn R, Klimberg I and Wajsman Z (2018) Persistent Acid-Fast Bacilli Following Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 141, NO. 5, (1197-1198), Online publication date: 1-May-1989.Ibrahiem E, Ghoneim M, Nigam V, Brailovsky C and Elhilali M (2018) Prophylactic Maltose Tetrapalmitate and Bacillus Calmette-Guerin Immunotherapy of Recurrent Superficial Bladder Tumors: Preliminary ReportJournal of Urology, VOL. 140, NO. 3, (498-500), Online publication date: 1-Sep-1988.Torrence R, Kavoussi L, Catalona W and Ratliff T (2018) Prognostic Factors in Patients Treated with Intravesical Bacillus Calmette-Guerin for Superficial Bladder CancerJournal of Urology, VOL. 139, NO. 5, (941-944), Online publication date: 1-May-1988.Bahnson R and Ratliff T (2018) Inhibition of Mouse Bladder Tumor Proliferation by Alpha Difluoromethylornithine and Interferon in Vitro and in VivoJournal of Urology, VOL. 139, NO. 6, (1367-1371), Online publication date: 1-Jun-1988.Hudson M, Ratliff T, Gillen D, Haaff E, Dresner S and Catalona W (2018) Single Course Versus Maintenance Bacillus Calmette-Guerin Therapy for Superficial Bladder Tumors: A Prospective, Randomized TrialJournal of Urology, VOL. 138, NO. 2, (295-298), Online publication date: 1-Aug-1987.DeKernion J (2018) Editorial CommentsJournal of Urology, VOL. 138, NO. 2, (298-298), Online publication date: 1-Aug-1987.Pansadoro V and De Paula F (2018) Intravesical Bacillus Calmette-Guerin in the Treatment of Superficial Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 138, NO. 2, (299-301), Online publication date: 1-Aug-1987.Jakse G, Loidl W, Seeber G and Hofstädter F (2018) Stage T1, Grade 3 Transitional Cell Carcinoma of the Bladder: An Unfavorable Tumor?Journal of Urology, VOL. 137, NO. 1, (39-43), Online publication date: 1-Jan-1987.Merguerian P, Donahue L and Cockett A (2018) Intraluminal Interleukin 2 and Bacillus Calmette-Guerin for Treatment of Bladder Cancer: A Preliminary ReportJournal of Urology, VOL. 137, NO. 2, (216-219), Online publication date: 1-Feb-1987.Marsh C, Torrey R, Woolley J, Barker G and Lau B (2018) Superiority of Intravesical Immunotherapy with Corynebacterium Parvum and Allium Sativum in Control of Murine Bladder CancerJournal of Urology, VOL. 137, NO. 2, (359-362), Online publication date: 1-Feb-1987.Huland H, Arndt R, Huland E, Loening T and Steffens M (2018) Monoclonal Antibody 486 P 3/12: A Valuable Bladder Carcinoma Marker for ImmunocytologyJournal of Urology, VOL. 137, NO. 4, (654-659), Online publication date: 1-Apr-1987.Soloway M and Perry A (2018) Bacillus Calmette-Guerin for Treatment of Superficial Transitional Cell Carcinoma of the Bladder in Patients who have failed Thiotepa and/or Mitomycin CJournal of Urology, VOL. 137, NO. 5, (871-873), Online publication date: 1-May-1987.Catalona W (2018) Editorial CommentJournal of Urology, VOL. 137, NO. 5, (873-873), Online publication date: 1-May-1987.Lamm D (2018) Editorial CommentsJournal of Urology, VOL. 138, NO. 2, (298-298), Online publication date: 1-Aug-1987. (2018) Reply by AuthorsJournal of Urology, VOL. 138, NO. 2, (298-298), Online publication date: 1-Aug-1987.Haaff E, Dresner S, Ratliff T and Catalona W (2018) Two Courses of Intravesical Bacillus Calmette-Guerin for Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 136, NO. 4, (820-823), Online publication date: 1-Oct-1986.Lamm D (2018) Editorial CommentJournal of Urology, VOL. 136, NO. 4, (823-824), Online publication date: 1-Oct-1986.Klimberg I and Wajsman Z (2018) Treatment for Muscle Invasive Carcinoma of the BladderJournal of Urology, VOL. 136, NO. 6, (1169-1175), Online publication date: 1-Dec-1986.Kelley D, Haaff E, Becich M, Lage J, Bauer W, Dresner S, Catalona W and Ratliff T (2018) Prognostic Value of Purified Protein Derivative Skin Test and Granuloma Formation in Patients Treated with Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 135, NO. 2, (268-271), Online publication date: 1-Feb-1986.Droller M (2018) Bacillus Calmette-Guerin in the Management of Bladder CancerJournal of Urology, VOL. 135, NO. 2, (331-333), Online publication date: 1-Feb-1986.Brosman S (2018) The Use of Bacillus Calmette-Guerin in the Therapy of Bladder Carcinoma in SituJournal of Urology, VOL. 134, NO. 1, (36-39), Online publication date: 1-Jul-1985.Lamm D (2018) Bacillus Calmette-Guerin Immunotherapy for Bladder CancerJournal of Urology, VOL. 134, NO. 1, (40-46), Online publication date: 1-Jul-1985.Catalona W (2018) Editorial CommentsJournal of Urology, VOL. 134, NO. 1, (46-47), Online publication date: 1-Jul-1985.Droller M (2018) Immunotherapy in Genitourinary NeoplasiaJournal of Urology, VOL. 133, NO. 1, (1-5), Online publication date: 1-Jan-1985.Morales A (2018) Long-Term Results and Complications of Intracavitary Bacillus Calmette-Guerin Therapy for Bladder CancerJournal of Urology, VOL. 132, NO. 3, (457-459), Online publication date: 1-Sep-1984.Netto N and Lemos G (2018) Bacillus Calmette-Guerin Immunotherapy of Infiltrating Bladder CancerJournal of Urology, VOL. 132, NO. 4, (675-676), Online publication date: 1-Oct-1984.Lamm D (2018) Editorial CommentsJournal of Urology, VOL. 132, NO. 4, (676-676), Online publication date: 1-Oct-1984.Droller M (2018) Editorial CommentsJournal of Urology, VOL. 132, NO. 4, (676-677), Online publication date: 1-Oct-1984.Adolphs H and Bastian H (2018) Chemoimmune Prophylaxis of Superficial Bladder CancerJournal of Urology, VOL. 129, NO. 1, (29-31), Online publication date: 1-Jan-1983.Mcroberts J (2018) Editorial CommentJournal of Urology, VOL. 129, NO. 1, (31-32), Online publication date: 1-Jan-1983.Brosman S (2018) Experience with Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, VOL. 128, NO. 1, (27-30), Online publication date: 1-Jul-1982.Lamm D, Thor D, Stogdill V and Radwin H (2018) Bladder Cancer ImmunotherapyJournal of Urology, VOL. 128, NO. 5, (931-935), Online publication date: 1-Nov-1982. (2018) Reply by AuthorsJournal of Urology, VOL. 127, NO. 2, (235-235), Online publication date: 1-Feb-1982.Morales A, Ottenhof P and Emerson L (2018) Treatment of Residual, Non-infiltrating Bladder Cancer with Bacillus Calmette-guerinJournal of Urology, VOL. 125, NO. 5, (649-651), Online publication date: 1-May-1981. Volume 124Issue 1July 1980Page: 38-42 Advertisement Copyright & Permissions© 1980 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Donald L. Lamm More articles by this author Daniel E. Thor More articles by this author Steven C. Harris More articles by this author Juan A. Reyna More articles by this author Valerie D. Stogdill More articles by this author Howard M. Radwin More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W229384513 created "2016-06-24" @default.
• W229384513 creator A5010400993 @default.
• W229384513 creator A5035896741 @default.
• W229384513 creator A5036331033 @default.
• W229384513 creator A5051182621 @default.
• W229384513 creator A5052301584 @default.
• W229384513 creator A5056355031 @default.
• W229384513 date "1980-07-01" @default.
• W229384513 modified "2023-10-14" @default.
• W229384513 title "Bacillus Calmette-guerin Immunotherapy of Superficial Bladder Cancer" @default.
• W229384513 cites W104522719 @default.
• W229384513 cites W1978720524 @default.
• W229384513 cites W1996124465 @default.
• W229384513 cites W2016134533 @default.
• W229384513 cites W2063969072 @default.
• W229384513 cites W2065157325 @default.
• W229384513 cites W2126436029 @default.
• W229384513 cites W2409912500 @default.
• W229384513 cites W4243650202 @default.
• W229384513 cites W4293241248 @default.
• W229384513 doi "https://doi.org/10.1016/s0022-5347(17)55282-9" @default.
• W229384513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6997513" @default.
• W229384513 hasPublicationYear "1980" @default.
• W229384513 type Work @default.
• W229384513 sameAs 229384513 @default.
• W229384513 citedByCount "281" @default.
• W229384513 countsByYear W2293845132012 @default.
• W229384513 countsByYear W2293845132013 @default.
• W229384513 countsByYear W2293845132014 @default.
• W229384513 countsByYear W2293845132015 @default.
• W229384513 countsByYear W2293845132016 @default.
• W229384513 countsByYear W2293845132017 @default.
• W229384513 countsByYear W2293845132018 @default.
• W229384513 countsByYear W2293845132019 @default.
• W229384513 countsByYear W2293845132020 @default.
• W229384513 countsByYear W2293845132021 @default.
• W229384513 countsByYear W2293845132022 @default.
• W229384513 countsByYear W2293845132023 @default.
• W229384513 crossrefType "journal-article" @default.
• W229384513 hasAuthorship W229384513A5010400993 @default.
• W229384513 hasAuthorship W229384513A5035896741 @default.
• W229384513 hasAuthorship W229384513A5036331033 @default.
• W229384513 hasAuthorship W229384513A5051182621 @default.
• W229384513 hasAuthorship W229384513A5052301584 @default.
• W229384513 hasAuthorship W229384513A5056355031 @default.
• W229384513 hasConcept C121608353 @default.
• W229384513 hasConcept C126322002 @default.
• W229384513 hasConcept C2777701055 @default.
• W229384513 hasConcept C2779150676 @default.
• W229384513 hasConcept C2780352672 @default.
• W229384513 hasConcept C2780674031 @default.
• W229384513 hasConcept C71924100 @default.
• W229384513 hasConcept C86803240 @default.
• W229384513 hasConcept C89423630 @default.
• W229384513 hasConceptScore W229384513C121608353 @default.
• W229384513 hasConceptScore W229384513C126322002 @default.
• W229384513 hasConceptScore W229384513C2777701055 @default.
• W229384513 hasConceptScore W229384513C2779150676 @default.
• W229384513 hasConceptScore W229384513C2780352672 @default.
• W229384513 hasConceptScore W229384513C2780674031 @default.
• W229384513 hasConceptScore W229384513C71924100 @default.
• W229384513 hasConceptScore W229384513C86803240 @default.
• W229384513 hasConceptScore W229384513C89423630 @default.
• W229384513 hasIssue "1" @default.
• W229384513 hasLocation W2293845131 @default.
• W229384513 hasLocation W2293845132 @default.
• W229384513 hasOpenAccess W229384513 @default.
• W229384513 hasPrimaryLocation W2293845131 @default.
• W229384513 hasRelatedWork W1488187260 @default.
• W229384513 hasRelatedWork W2026443803 @default.
• W229384513 hasRelatedWork W2051150963 @default.
• W229384513 hasRelatedWork W2100228124 @default.
• W229384513 hasRelatedWork W2261933510 @default.
• W229384513 hasRelatedWork W2342065801 @default.
• W229384513 hasRelatedWork W2353334772 @default.
• W229384513 hasRelatedWork W2946377256 @default.
• W229384513 hasRelatedWork W3162877177 @default.
• W229384513 hasRelatedWork W3196202855 @default.
• W229384513 hasVolume "124" @default.
• W229384513 isParatext "false" @default.
• W229384513 isRetracted "false" @default.
• W229384513 magId "229384513" @default.
• W229384513 workType "article" @default.